AIM ImmunoTech (STU:HXB2) Long-Term Capital Lease Obligation : €0.49 Mil (As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is AIM ImmunoTech Long-Term Capital Lease Obligation?

AIM ImmunoTech's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.49 Mil.

AIM ImmunoTech's quarterly Long-Term Capital Lease Obligation declined from Sep. 2023 (€0.51 Mil) to Dec. 2023 (€0.45 Mil) but then increased from Dec. 2023 (€0.45 Mil) to Mar. 2024 (€0.49 Mil).

AIM ImmunoTech's annual Long-Term Capital Lease Obligation increased from Dec. 2021 (€0.10 Mil) to Dec. 2022 (€0.62 Mil) but then declined from Dec. 2022 (€0.62 Mil) to Dec. 2023 (€0.45 Mil).

AIM ImmunoTech Long-Term Capital Lease Obligation Historical Data

The historical data trend for AIM ImmunoTech's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech Long-Term Capital Lease Obligation Chart

AIM ImmunoTech Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

2.00

1.65

0.10

0.62

0.45

AIM ImmunoTech Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															0.59	0.55	0.51	0.45	0.49

AIM ImmunoTech (STU:HXB2) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

AIM ImmunoTech Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of AIM ImmunoTech's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

AIM ImmunoTech (STU:HXB2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (STU:HXB2) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

AIM:USA HXB2:Germany

Address

2117 SW Highway 484, Ocala, FL, USA, 34473

Website

https://www.aimimmuno.com

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

AIM ImmunoTech (STU:HXB2) Headlines

No Headlines